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ABSTRACT
Objective: To show noninferiority of a limited-excision (resection of the dysplastic lesion 
only) vs. classical Large Loop Excision of the Transformation Zone (LLETZ).
Methods: In this prospective, randomized, multicenter trial, women with human 
papillomavirus (HPV) positive cervical intraepithelial neoplasia grade 3 were randomized 
into two groups (1:1). Primary outcome was the rate of negative HPV tests after 6 months, 
secondary outcomes included cone size, complete resection rates as well as cytological and 
histological results after 6 and 12 months. A sample size of 1,000 was calculated to show 
noninferiority of the limited-excision compared to the LLETZ group using a noninferiority 
margin of 5%. Enrollment was stopped after 100 patients due to slow accrual.
Results: Patients in the limited-excision group did not show a lower number of negative HPV 
tests (78% [LLETZ]−80% [limited-excision]=−2%; 90% confidence interval=−15%, 12%). 
The limited-excision resulted in a substantially lower cone size (LLETZ: 1.97 mL vs. limited-
excision: 1.02 mL; p<0.001) but higher numbers of involved margins (LLETZ: 8% vs. limited-
excision: 20%). Although postoperative cytological results slightly differed, histological results 
were similar in both groups. One limited-excision patient received immediate re-conisation, 
whereas one patient in each group was scheduled for re-conisation after 6 months.
Conclusion: The limited-excision could represent a promising option to reduce the surgical extent 
of conisations while maintaining oncological safety. The trial was not sufficiently powered to 
reach statistical significance due to early termination. Nevertheless, the study provides important 
insights in the feasibility of a limited-excision and could serve as a pilot study for future trials.
Trial Registration: German Clinical Trials Register Identifier: DRKS00006169
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INTRODUCTION
Cervical cancer is the second most common malignancy in women. In 2012, 527,600 
patients were diagnosed worldwide and 265,700 women died from this disease [1]. Cervical 
intraepithelial neoplasia (CIN) is the direct precursor lesion of squamous epithelial cervical 
cancer and is classified in high-grade (CIN 2–3) and low-grade (CIN 1) dysplastic lesions. Every 
year, over 1 million women receive the diagnosis of CIN 1 and half a million are diagnosed 
with high-grade dysplasia [2]. While the median age of patients with cervical cancer is 49, 
patients with CIN are typically 10–15 years younger and of childbearing age [3,4]. According 
to international guidelines, non-pregnant women with the diagnosis of CIN 3 receive surgical 
treatment in terms of conisation [5]. In accordance with the definition of the Large Loop 
Excision of the Transformation Zone (LLETZ) operation, the transformation zone should be 
removed in addition to the dysplasia itself [6]. It is well known that the size of the removed 
cone directly correlates with the risk for preterm delivery [7-10]. Therefore, a reduction in 
cone size could potentially be of benefit for patients who still wish to conceive. In addition, 
a limited-excision could also be of advantage for other patient groups, e.g., women using 
therapeutic anticoagulation who would profit from a limited surgical wound. Nowadays, many 
surgeons already tend to reduce the size of the removed cone. However, it is unknown if a 
reduction in radicality results in oncologically equally safe outcomes. Strander et al. [11] for 
example observed that the risk for the development of cervical cancer in patients who were 
treated for cervical dysplasia increased progressively between 1958 and 2008. According to the 
authors this might be attributed to a reduction of the surgical extent over time.
In awareness of the need to remove as little tissue as possible to minimize surgery-associated 
risks but at the same time to maintain comparable oncological safety, we designed this trial 
to analyze whether a limited-excision approach is non-inferior in terms of postoperative 
negative human papillomavirus (HPV) rates compared to a classical LLETZ operation.
MATERIALS AND METHODS
The Evaluation of Clinical Outcome after Reduction of Conisation Size (ECO-ROCS) trial 
was a multicenter, prospective, noninferiority, randomized controlled trial. This study 
investigated whether the removal of the colposcopically visible lesion only is noninferior in 
terms of oncological safety compared to the classical LLETZ operation, in which the lesion 
including the transformation zone is removed. Sample size was calculated using the POWER 
procedure for noninferiority test in SAS 9.3 software (SAS Institute, Cary, NC, USA) with the 
parameters α=0.05, power=80% for a one-sided test and a noninferiority margin of 5% for 
the HPV negativity rate difference (LLETZ−limited-excision). A rate of 90% negative HPV 
tests was assumed as the expected postoperative HPV rate for LLETZ conisations 6 months 
postoperatively [12]. A 10% drop-out rate was added to the calculated sample size of 892 
patients, whereby a total patient number of 1,000 patients was determined for the study.
Trial protocol and informed consent documents have been approved by the University of 
Munich Institutional Review Board (project number 275-14, 10.07.2014) as well as the local 
ethics committees and/or state chambers of physicians of all other participating study centers.
Overall, 14 German study centers, all of which run a specialized dysplasia clinic, agreed to 
include patients for this trial. The participating study centers and investigators are listed in 
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the German Clinical Trials Register (DRKS00006169). All participants completed written 
informed consent forms prior to participation in the trial.
Inclusion and exclusion criteria are depicted in Table 1. Patients were randomized 1:1 using 
a web-based randomization technique called “Randoulette,” designed by the Institute for 
Medical Informatics, Biometry and Epidemiology, University of Munich, Germany [13]. Only 
the randomizing surgeons and the web-administrator were eligible to access the system. 
Randomization was performed using an unblended, stratified block randomization.
After randomization, the respective surgical method was carried out under colposcopic 
control using a thin, low-voltage, electrified wire loop known as a loop electrosurgical 
excision procedure electrode. In the LLETZ group, the lesion was removed in addition to 
the transformation zone. To define the extent of the transformation zone, an area of at least 
4 mm surrounding the squamocolumnar junction was used. If the extent of the lesion was 
larger or colposcopic findings suggested a greater transformation zone, the resected area 
was adapted respectively. In case of limited-excision, only the colposcopically visible CIN-
lesion was removed with a resection margin of 2 mm. An endocervical extent of 6–8 mm 
was aimed for regardless of the allocated surgical method. No additional endocervical cone 
was removed. Fig. 1 shows a graphic illustration of both techniques. For further information 
and examples on both methods please refer to the published study protocol [14]. Cone 
volume was determined immediately after the operation in both groups using the principle 
of Archimedes [15]. The removed specimen was placed in a 15 mL tube filled with a pre-
specified amount of sterile sodium chloride. An increase of saline volume measured in 
mL was interpreted as the volume of conisation specimen [15]. Post-operative histological 
analyses were performed at the local institutes of pathology by blinded pathologists and 
specimens were evaluated according to national guidelines. In addition to the grade and 
extent of dysplasia, surgical margins were assessed for the detection of dysplastic cells.
Primary endpoint of the study was the rate of negative HPV tests 6 months postoperatively 
since a negative postoperative HPV test is considered to be the test of cure [16]. Only HPV test 
kits that fulfilled the published criteria of Meijer et al. [17] were allowed for use in this study. 
Secondary endpoints were cone size, complete resection rate, cytological and histological 
results after 6 and 12 months as well as an additional HPV test 12 months after the operation. 
At follow-up visits, colposcopy, HPV tests, and Pap smears were collected. Biopsies were 
taken only in case of suspicious colposcopic findings and only the suspicious lesion itself 
was biopsied, i.e., 4-quadrant biopsy or endocervical curettage was not mandatory. HPV, 
cytological and histological analyses were carried out locally in each participating department 
by blinded cytologists and histopathologists.
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Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Biopsy proven CIN 3 Pregnancy at time of inclusion and up to 6 months after the surgery
Positive HPV high risk test Immunosuppressive medication including glucocorticoids
Colposcopically visible lesion Prior HPV vaccination
Age ≥18 years Known malignancy
Premenopausal Known HIV infection
Written informed consent Prior treatment for CIN 3
Prior cervical surgeries
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
1. Statistical analysis
To assess if the HPV rate of the limited-excision group was noninferior to the LLETZ group 
after 6 months, the difference (LLETZ−limited-excision) of the observed HPV negative rates 
as well as a corresponding 90% confidence interval (CI) using Newcombe (hybrid) Score were 
calculated. Noninferiority was established if the upper limit of the 90% CI of the rate difference 
was below the pre-specified noninferiority margin of 5%. Effects of secondary nominal 
endpoints were described using rates and rate differences with corresponding 90% CI using 
Newcombe (hybrid) Score method. The difference in cone size was described using mean and 
was analyzed using the nonparametric Wilcoxon-Mann-Whitney U test. The error level for both 
tests was set at α=0.05. All analyses were carried out using the SAS 9.4 (SAS Institute).
RESULTS
1. Peri-operative
In total 100 patients (n=50 per group) recruited in four study centers were included 
between September 2014 and December 2016. After this period, the trial was terminated due 
to slow recruitment.
Median age of patients in the LLETZ group was 31.6 years (range, 23.8–47.3) and 31.0 (range, 
23.9–43.4) in the limited-excision group.
Mean cone size in patients with LLETZ was almost double the volume of the size in patients, 
who received the limited-excision method (limited-excision: 1.02 mL [median: 0.6 mL] vs. 
LLETZ: 1.97 mL [median: 2.0 mL]; p<0.001).
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4 mm around the SCJ representing the minimum








Resection margin Resection margin
Resection margin
SCJ
Fig. 1. (A) Graphic example of a LLETZ conisation using a minimum of 4 mm around the SCJ. (B) Graphic example 
of a limited-excision conisation using a distance of 2 mm around the lesion(s). Adapted from Schwarz et al. [14]. 
CIN, cervical intraepithelial neoplasia; LLETZ, Large Loop Excision of the Transformation Zone; SCJ, 
squamocolumnar junction.
LLETZ operation yielded 92% clear margins (46/50) compared to 80% of patients (40/50) in 
the limited-excision group (difference=12%; 90% CI=0%–24%). The patients of 3 (LLETZ) 
vs. 9 (limited-excision) showed high-grade dysplasia (CIN 2 or CIN 3) either at the endo- or 
ectocervical border. The option of immediate re-conisation was discussed with all patients 
and one woman in the limited-excision group decided to undergo surgery. Peri-operative 
results are summarized in Table 2.
2. Post-operative (6 months)
Patients were scheduled for follow-up visits 6 and 12 months after the operation. All follow-
up results after 6 months are summarized in Table 3. Detailed cytological and histological 
results can be found in Supplementary Tables 1 and 2.
Eighty percent (40/50 patients) in the limited-excision group compared to 78% (39/50) in the 
LLETZ group were HPV high risk negative 6 months postoperatively (difference=−2%; 90% 
CI=−15%, 12%).
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Table 2. Peri-operative patient characteristics
Characteristics LLETZ (n=50) Limited-excision (n=50)
Median age (yr) 31.6 31.0
HPV high risk
Negative 0 (0) 0 (0)
Positive 50 (100) 50 (100)
HPV 16+ 22 (44) 14 (28)
HPV 18+ 1 (2) 2 (4)
Pap smear
Negative* 0 (0) 1 (2)
Suspicious 50 (100) 49 (98)
Histology
Clear margins 46 (92) 40 (80)
Involved margins 4 (8) 10 (20)
Mean cone size (mL; n=49) 1.97 1.02†
No. of re-conisations 0 1
Values are presented as number (%).
HPV, human papillomavirus; LLETZ, Large Loop Excision of the Transformation Zone; NILM, negative for 
intraepithelial lesion or malignancy.
*Only NILM Pap smears are categorized as negative; †p<0.001.
Table 3. Post-operative (6 months) patient characteristics
Characteristics LLETZ (n=50) Limited-excision (n=50) Difference (90% CI)
HPV high risk (n=49) −2% (−15%, 12%)
Negative 39 (78) 39 (80)
Positive 11 (22) 10 (20)
HPV 16+ 6 (12) 4 (8)
HPV 18+ 1 (2) 0 (0)
Pap smear 8% (−7%, 23%)
Negative* 35 (70) 31 (62)
Suspicious 15 (30) 19 (38)
Histology −2% (−13%, 9%)
Normal 43 (86) 44 (88)
Dysplastic† 7 (14) 6 (12)
No. of re-conisations 1 1 -
Values are presented as number (%).
CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LLETZ, Large Loop 
Excision of the Transformation Zone; NILM, negative for intraepithelial lesion or malignancy.
*Only NILM Pap smears are categorized as negative; †Dysplastic histology includes CIN 1–3 lesions. Patients 
on whom no biopsies had been performed due to unsuspicious colposcopy as well as patients with benign 
pathologic reports are summarized under the histological category “normal.”
Four patients in the limited-excision group and 6 patients in the LLETZ group were 
persistently HPV 16 positive, whereas no patient in the limited-excision group and only 1 
patient in the LLETZ group was persistently HPV 18 positive. With regards to secondary 
endpoints, cytological results differed slightly in both groups. Seventy percent (35/50 LLETZ 
patients) vs. 62% (31/50 limited-excision patients) showed a negative for intraepithelial lesion 
or malignancy (NILM) smear, 30% (15/50 LLETZ patients) vs. 38% (19/50 limited-excision 
patients) were diagnosed with a suspicious smear (difference=8%; 90% CI=−7%, 23%).
The higher number of suspicious Pap smear results did not translate into a higher amount of 
biopsy-proven high grade dysplastic lesions: Histological results after 6 months were similar 
in both groups (88% limited-excision vs. 86% LLETZ patients showed no dysplastic lesions; 
difference=−2%; 90% CI=−13%, 9%). One patient in each group was diagnosed with CIN 3 
and scheduled for re-conisation.
3. Post-operative (12 months)
Twelve months postoperatively 88% (37/42, LLETZ) compared to 92% (35/38, limited-
excision) of patients showed negative HPV high risk test results (difference=−4%; 90% 
CI=−15%, 8%). Seventy-three percent (30/41, LLETZ) vs. 89% (34/38, limited-excision) had a 
Pap smear result without evidence of dysplasia (difference=−16%; 90% CI=−30%, −17%). Two 
CIN 1 and one CIN 2 were diagnosed in the LLETZ group, whereas there was no dysplasia 
histologically detected in the limited-excision conisation group. No patient was scheduled for 
re-conisation. All follow-up results after twelve months are summarized in Table 4.
DISCUSSION
This is the first prospective, randomized trial comparing a limited-excision approach with 
classical LLETZ in terms of oncological safety.
Primary goal of the study was to investigate if the upper limit of the 90% CI (difference of 
negative HPV tests LLETZ−limited-excision after 6 months) was below the pre-specified 5% 
noninferiority margin. HPV status was taken as a surrogate parameter to assess oncological 
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Table 4. Post-operative (12 months) patient characteristics
Characteristics LLETZ (n=42) Limited-excision (n=38) Difference (90% CI)
HPV high risk −4% (−15%, 8%)
Negative 37 (88) 35 (92)
Positive 5 (12) 3 (8)
HPV 16+ 4 (11) 4 (11)
HPV 18+ 0 (0) 1 (3)
Pap smear (n=41) −16% (−30%, −2%)
Negative* 30 (73) 34 (89)
Suspicious 11 (27) 4 (11)
Histology N/A
Normal 39 (93) 38 (100)
Dysplastic† 3 (7) 0 (0)
No. of re-conisations 0 0 -
Values are presented as number (%).
CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LLETZ, Large Loop 
Excision of the Transformation Zone; N/A, non-applicable; NILM, negative for intraepithelial lesion or malignancy.
*Only NILM Pap smears are categorized as negative; †Dysplastic histology includes CIN 1–3 lesions. Patients 
on whom no biopsies had been performed due to unsuspicious colposcopy as well as patients with benign 
pathologic reports are summarized under the histological category “normal.”
safety, since a negative HPV test is generally accepted as test of cure [16]. This is due to the 
fact, that the negative predictive value for a negative HPV test after conisation is between 92% 
and 100% [18-22]. However, no long-term follow-up was assessed which would be necessary 
to ultimately rule out increased cervical cancer rates after years.
Surprisingly in this study, the limited-excision group tended to perform better compared to 
the LLETZ group in terms of HPV negativity 6 months after the operation (difference negative 
HPV tests LLETZ−limited-excision=−2%; 90% CI=−15%–12%). This trend even increased after 
12 months (difference=−4%; 90% CI=−15%, 8%). Noninferiority margin was pre-defined to 
be 5% after 6 months according to clinical considerations. Therefore, noninferiority was not 
established (upper CI limit: 12%) which is likely due to early termination and resulting limited 
sample size. Nevertheless, despite the fact that only 10% of the initially planned patient 
number was included, the results indicate that patients in the limited-excision group show 
only at maximum 12% (after 6 months), respectively 8% (after 12 months) lower HPV negative 
rates compared to the LLETZ group. Depending on the individual patient, this risk might be 
acceptable, e.g., for patients of childbearing age or with certain comorbidities that require a 
surgical wound as small as possible. HPV types 16 and 18 are known to cause 70% of cervical 
cancers [23]. We therefore analyzed these HPV types in both patient groups. While patients in 
the LLETZ group showed a higher pre-operative percentage of HPV 16 positivity (LLETZ: 44% 
vs. limited-excision: 28%) the ratio of patients who turned negative in the first post-operative 
control after 6 months was similar (LLETZ: 3.7 vs. limited-excision: 3.5). Numbers of HPV 18 
positive patients (pre-operative: LLETZ 2% vs. limited-excision 4%, post-operative LLETZ: 
2% vs. limited-excision: 0%) are very limited but neither point to an increased risk of HPV 18 
persistence in the limited-excision group. However, these results could have been influenced 
by post-operative HPV vaccination which has not been monitored.
Secondary endpoints in this study were cone sizes and complete resection rates as well as 
cytological and histological follow-up results after 6 and 12 months.
Mean cone size in the limited-excision group was almost half of the volume compared to the 
LLETZ group (LLETZ: 1.97 mL vs. limited-excision: 1.02 mL; p<0.001). The reduction in cone 
size is particularly important with regards to obstetrical complications since it has been shown 
that larger cone sizes correlate with an increased risk of pre-term delivery [7-10]. Nevertheless, 
it needs to be mentioned as a limitation that the amount of fulguration which has not been 
monitored in this study, could also contribute to the extent of damaged cervical tissue.
The number of involved margins was 2.5 times higher in the limited-excision vs. the LLETZ 
group (4/50 vs. 10/50) which reflects the difficulty of a limited-excision approach. Given that 
in this study all surgeries were performed by surgeons experienced in the field of colposcopy-
guided conisations, general implementation of the limited-excision approach could have an 
impact particularly on cone sizes and complete resection rates.
Interestingly, the finding of increased involved margins in the limited-excision group did 
not translate into higher numbers of histologically confirmed high-grade dysplasias during 
follow-up (6 months, LLETZ: 14% vs. limited-excision: 12%; 12 months, LLETZ: 7% vs. 
limited-excision: 0%). Only cytological results at the 6 months-visit showed higher numbers 
of suspicious smears in the limited-excision group (LLETZ: 30% vs. limited-excision: 38%). 
However, the discrepancy between cytological and histological findings is in line with 
published literature that also shows a tendency for cytological overcall of results [24].
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In conclusion, our results point into the direction that a limited-excision approach could 
represent a safe alternative for patients with high-grade dysplasia. However, due to early 
termination the trial was not sufficiently powered to establish statistical significance. 
Additionally, it needs to be mentioned that the limited-excision approach goes along with 
certain limitations. To enable a targeted excision of the lesion, the whole lesion needs to 
be colposcopically accessible. Especially with older patients who are more likely to have a 
T3 type transformation zone, these criteria could be difficult to apply. Although there was 
no age limitation in our study, the number of patients older than 40 was still limited (n=5) 
and therefore did not allow for evaluation of outcome specifically in this patient population. 
Therefore, despite promising initial results, further studies with higher patient numbers are 
needed to confirm oncological safety of a limited-excision approach and should also investigate 
the impact on various risks like post-operative bleeding, scarring or obstetrical outcome.
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